Feature | May 15, 2014

Linking Vascular Inflammation to Obesity, Atherosclerosis


May 15, 2014 — A clinical study in The Journal of Experimental Medicine shows that I?B kinase ? (IKK?) functions in smooth muscle cells to regulate vascular inflammatory responses and atherosclerosis development.

Inflammatory responses are the driving force of atherosclerosis, a process that involves the hardening and thickening of artery walls due to excess fatty deposits. IKK? is a central coordinator of inflammatory responses that has been implicated in vascular diseases, but its role in atherosclerosis has been unclear.

Now, Changcheng Zhou and colleagues from the University of Kentucky show that deficiency of IKK? in smooth muscle cells decreases vascular inflammation and atherosclerosis development in mice. Surprisingly, the lack of IKK? also blocks the differentiation of fat cells and causes an accumulation of body fat precursor cells, thus protecting the animals from diet-induced obesity. These novel findings suggest that the kinase acts as a regulator of fat cell differentiation. The use of IKK? inhibitors may therefore provide an innovative treatment for atherosclerosis, obesity, and metabolic disorders.

Sui, Y., et al. 2014. J. Exp. Med.doi:10.1084/jem.20131281

For more information: www.jem.org


Related Content

News | Cardiovascular Clinical Studies

May 6, 2026 — Image Analysis Group (IAG), a global imaging CRO headquartered in London, U.K., and HeartcoR Solutions ...

Home May 06, 2026
Home
News | Cardiovascular Clinical Studies

April 9, 2026 — Mount Sinai researchers have created an analytic tool using machine learning that can predict ...

Home April 14, 2026
Home
News | Cardiovascular Clinical Studies

April 13, 2026 —The American Heart Association (AHA) has granted Case Western Reserve University the Rapid Impact ...

Home April 13, 2026
Home
News | Cardiovascular Clinical Studies

April 2, 2026 — Iterative Health and US Heart & Vascular (USHV) have announced a strategic partnership to advance ...

Home April 02, 2026
Home
News | Cardiovascular Clinical Studies

March 4, 2026 — UltraSight, a provider of AI-guided cardiac imaging workflows, has announced Late-Breaking clinical ...

Home March 04, 2026
Home
News | Cardiovascular Clinical Studies

Feb. 9, 2026 — HTA and MedAxiom have opened applications for the 2026 HeartX program, a cardiovascular-focused ...

Home February 18, 2026
Home
News | Cardiovascular Clinical Studies

Jan. 5, 2026 — Medera Inc., a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by ...

Home January 05, 2026
Home
News | Cardiovascular Clinical Studies

Nov. 10, 2025 —Genomics, a science-led techbio company, has today announced new research that suggests polygenic risk ...

Home November 12, 2025
Home
News | Cardiovascular Clinical Studies

Oct. 21, 2025 – AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG ...

Home October 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and ...

Home August 25, 2025
Home
Subscribe Now